1-(piperazin-1-yl)cyclohexanecarbonitrile | 874623-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(piperazin-1-yl)cyclohexanecarbonitrile
• 英文别名: 1-Piperazin-1-ylcyclohexanecarbonitrile；1-piperazin-1-ylcyclohexane-1-carbonitrile
• CAS: 874623-59-3
• 化学式: C₁₁H₁₉N₃
• mdl: MFCD07692336
• 分子量: 193.292
• InChiKey: COPVGSODXBYSPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  39.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(piperazin-1-yl)cyclohexanecarbonitrile 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 24.0h， 生成 2-Ethoxy-N-((1-(piperazin-1-YL)cyclohexyl)methyl)benzamide
  参考文献：
  名称：

  Discovery of a novel series of selective HCN1 blockers

  摘要：

  The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy- N-(( 1-(4-isopropylpiperazin-1-yl) cyclohexyl) methyl) benzamide. The work leading to the discovery of this compound is described herein. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.051
• 作为产物：
  描述：

  4-(1-Cyano-cyclohexyl)-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到1-(piperazin-1-yl)cyclohexanecarbonitrile
  参考文献：
  名称：

  Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1

  摘要：

  The design, synthesis, and structure-activity relationships (SAR) of a series of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1 (GlyT-1) are described. Optimization of the benzamide and central ring components of the core scaffold led to the identification of a GlyT-1 inhibitor that demonstrated in vivo activity in a rodent cerebral spinal fluid (CSF) glycine model. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.006

文献信息

• Ligands of melanocortin receptors and compositions and methods related thereto
  申请人：Neurocrine Biosciences Inc.

  公开号：US20030158209A1

  公开（公告）日：2003-08-21

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): 1 including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein A, m, n, R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 W 1 , W 2 , W 3 , W 4 , Y 1 , Y 2 , Y 3 and Y 4 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  具有治疗基于黑素皮质素受体的疾病的功效的化合物，其作为黑素皮质素受体配体发挥作用。这些化合物具有以下结构（I）：包括立体异构体、前药和其在药用上可接受的盐，其中A、m、n、R1、R2、R3a、R3b、R4、R5、R6W1、W2、W3、W4、Y1、Y2、Y3和Y4如本文所定义。还公开了含有结构（I）的化合物的药物组合物，以及与其使用相关的方法。
• [EN] LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO<br/>[FR] LIGANDS DE RECEPTEURS DE LA MELANOCORTINE ET COMPOSITIONS ET METHODES ASSOCIEES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2003031410A1

  公开（公告）日：2003-04-17

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders, and may be used to treat disorders or illnesses including eiating disorders, cachexia, obesity, diabetes, metabolic disorders, inflammation, pain, skin disorders; skin and hair coloration, male and female sexual dysfuntion, erectile dysfunction, dry eye acne and/or Cushing's disease. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein A, m, n R1, R2, R3a, R3b, R4, R5, R6, W1, W2, W3, W4, Y1, Y2, Y3 and Y4 area defined herin. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  具有治疗黑素皮质素受体基础疾病功效的化合物，可用于治疗包括进食障碍、消瘦、肥胖症、糖尿病、代谢紊乱、炎症、疼痛、皮肤疾病、皮肤和头发着色、男性和女性性功能障碍、勃起功能障碍、干眼症、痤疮和库欣综合症等疾病或疾病。该化合物具有以下结构（I）：包括立体异构体、前药和其药学上可接受的盐，其中A、m、n、R1、R2、R3a、R3b、R4、R5、R6、W1、W2、W3、W4、Y1、Y2、Y3和Y4在此定义。还公开了含有结构（I）的化合物的药物组成物，以及与其使用相关的方法。
• GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF
  申请人：CIOFFI Christopher L.

  公开号：US20110312931A1

  公开（公告）日：2011-12-22

  The compounds of the present invention are represented by the following formula (I): wherein the substituents R 1 , R 2 , R 3 , R 4 , (R 5 ) m , R 6 , A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.

  本发明的化合物由以下公式（I）表示：其中，取代基R1、R2、R3、R4、（R5）m、R6、A、X和Y的定义如本文所述。这些化合物可用于治疗由抑制GlyT-1引起或依赖于GlyT-1抑制的疾病的方法。
• Substituted amide derivatives having multimodal activity against pain
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：US10428051B2

  公开（公告）日：2019-10-01

  The present invention relates to substituted amide derivatives having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及对σ（σ）受体和μ-阿片受体具有双重药理活性的取代酰胺衍生物，涉及此类化合物的制备工艺，涉及包含这些化合物的药物组合物，还涉及它们在治疗中的用途，特别是用于治疗疼痛。
• LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO
  申请人：Neurocrine Biosciences, Inc.

  公开号：EP1465867A1

  公开（公告）日：2004-10-13